Black Diamond Therapeutics Receives 'Moderate Buy' Rating from Analysts

Shares of the precision oncology company have an average 12-month price target of $9.83

Apr. 17, 2026 at 8:36am

Got story updates? Submit your updates here. ›

A cinematic close-up of heavy, metallic pharmaceutical research equipment and machinery, conveying the complex, technical nature of drug development.Analysts see potential upside in Black Diamond Therapeutics' precision oncology drug pipeline, reflected in the 'Moderate Buy' rating and $9.83 average price target.Cambridge Today

Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) have received an average 'Moderate Buy' rating from the eight analysts currently covering the stock, according to Marketbeat Ratings. The analysts have an average 12-month price target of $9.83 on the stock.

Why it matters

Black Diamond Therapeutics is a precision oncology company focused on developing small-molecule therapies that target specific genetic mutations in cancer. The 'Moderate Buy' rating and price target from analysts suggest potential upside for the company's stock, which could signal investor confidence in its drug development pipeline.

The details

One analyst has rated the stock with a 'sell' rating, two have given a 'hold' rating, and five have issued a 'buy' rating on the company. Wedbush recently boosted its price target on Black Diamond Therapeutics from $13 to $14 and maintained an 'outperform' rating, while Zacks Research lowered its rating from 'strong-buy' to 'hold'.

  • Black Diamond Therapeutics reported its latest quarterly earnings on March 16, 2026.

The players

Black Diamond Therapeutics, Inc.

A precision oncology company focused on developing small-molecule therapies that target specific genetic mutations in cancer.

Wedbush

An investment research and financial services firm that has provided coverage and analysis on Black Diamond Therapeutics.

Zacks Research

An investment research firm that has provided coverage and analysis on Black Diamond Therapeutics.

Got photos? Submit your photos here. ›

The takeaway

The 'Moderate Buy' rating and $9.83 average price target from analysts suggest potential upside for Black Diamond Therapeutics' stock, reflecting investor confidence in the company's precision oncology drug development pipeline.